<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383019</url>
  </required_header>
  <id_info>
    <org_study_id>A6641050</org_study_id>
    <nct_id>NCT00383019</nct_id>
  </id_info>
  <brief_title>A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).</brief_title>
  <official_title>A 8-Week, Randomized, Double-Masked, Parallel Group, Phase III Study Comparing The Efficacy And Safety Of Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in
      Japanese patients with POAG or OH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Intraocular Pressure (IOP) From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of IOP From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of IOP From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=15 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=16 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=17 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=18 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP Reduction of &gt;=2 mmHg From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP Reduction of &gt;=3 mmHg From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">289</enrollment>
  <condition>Glaucoma, Primary Open Angle (POAG)</condition>
  <condition>Ocular Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalacom (KP2035)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4
             weeks or more.

        Exclusion Criteria:

          -  History of no-response to timolol

          -  History of trabeculectomy

          -  History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ichinomiya</city>
        <state>Aichi</state>
        <zip>491-0837</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ichinomiya</city>
        <state>Aichi</state>
        <zip>491-0858</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <zip>275-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>001-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>001-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>004-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0020</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koube</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-0934</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>248-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>228-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Kokkaido</state>
        <zip>003-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <zip>611-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miyakonojo</city>
        <state>Miyazaki</state>
        <zip>885-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <zip>360-0843</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1116</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fuji</city>
        <state>Shizuoka</state>
        <zip>416-0952</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fuji</city>
        <state>Shizuoka</state>
        <zip>419-0204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mishima</city>
        <state>Shizuoka</state>
        <zip>411-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Susono</city>
        <state>Shizuoka</state>
        <zip>410-1102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>102-8161</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamura</city>
        <state>Tokyo</state>
        <zip>205-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>125-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kiyose</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>152-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <zip>180-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <zip>180-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>144-052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <zip>157-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>160-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taito-ku</city>
        <state>Tokyo</state>
        <zip>110-015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fujuoka</city>
        <zip>812-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0133</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Niigata</city>
        <zip>951-8122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>537-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>557-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sugita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6641050&amp;StudyName=A%20Study%20Comparing%20Xalacom%20And%20Xalatan%20In%20Patients%20With%20Primary%20Open%20Angle%20Glaucoma%20%28POAG%29%20Or%20Ocular%20Hypertension%20%28OH%29.%0D</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2006</study_first_posted>
  <results_first_submitted>October 1, 2008</results_first_submitted>
  <results_first_submitted_qc>April 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2009</results_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>55 centers in Japan</recruitment_details>
      <pre_assignment_details>300 subjects were treated with Xalatan in Run-in period. (Run-in period: subjects treated with Xalatan (0.005% latanoprost eye drop), one drop, once daily in the evening (20:00-23:00).) Of these, 289 subjects were assigned to groups (144 in KP2035 group and 145 in Xalatan group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>KP2035 Group</title>
          <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="P2">
          <title>Xalatan Group</title>
          <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KP2035 Group</title>
          <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="B2">
          <title>Xalatan Group</title>
          <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="289"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Intraocular Pressure (IOP) From Baseline to Week 8</title>
        <description>Value at Week 8 minus value at baseline</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The primary efficacy analysis population was the Intent-to-treat population (ITT) which consisted of all subjects treated with the study drug as randomized. If there were any missing IOP values at Week 8, the data were supplemented by LOCF (Last Observation Carried Forward) using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Intraocular Pressure (IOP) From Baseline to Week 8</title>
          <description>Value at Week 8 minus value at baseline</description>
          <population>The primary efficacy analysis population was the Intent-to-treat population (ITT) which consisted of all subjects treated with the study drug as randomized. If there were any missing IOP values at Week 8, the data were supplemented by LOCF (Last Observation Carried Forward) using data at Week 4.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" spread="2.40" lower_limit="-2.92" upper_limit="-2.25"/>
                    <measurement group_id="O2" value="-1.62" spread="2.51" lower_limit="-1.96" upper_limit="-1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size of 132 subjects per group would be needed to detect the 1.5 mmHg treatment difference with 3.75 mmHg of the standard deviation at a power of 90% in two-sided t tests with a 0.05 level of confidence. One hundred and forty six subjects per group (total of 292) were planned to allow for drop outs and withdrawals.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) was applied using the treatment groups as a factor and baseline IOP of the study eyes as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as &quot;mean change from baseline to Week 8 in KP2035 group&quot; minus &quot;mean change from baseline to Week 8 in Xalatan group&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of IOP From Baseline to Week 4</title>
        <description>Value at Week 4 minus value at baseline</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of IOP From Baseline to Week 4</title>
          <description>Value at Week 4 minus value at baseline</description>
          <population>ITT</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="2.25" lower_limit="-2.83" upper_limit="-2.17"/>
                    <measurement group_id="O2" value="-1.17" spread="2.09" lower_limit="-1.50" upper_limit="-0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The analysis of covariance (ANCOVA) was applied using the treatment groups as a factor and baseline IOP of the study eyes as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>-0.87</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as &quot;mean change from baseline to Week 4 in KP2035 group&quot; minus &quot;mean change from baseline to Week 4 in Xalatan group&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of IOP From Baseline to Week 8</title>
        <description>Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of IOP From Baseline to Week 8</title>
          <description>Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.67" spread="12.10" lower_limit="-14.40" upper_limit="-10.93"/>
                    <measurement group_id="O2" value="-7.69" spread="10.56" lower_limit="-9.42" upper_limit="-5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The analysis of covariance (ANCOVA) was applied using the treatment groups as a factor and baseline IOP of the study eyes as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.43</ci_lower_limit>
            <ci_upper_limit>-2.52</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as &quot;percent change from baseline to Week 8 in KP2035 group&quot; minus &quot;percent change from baseline to Week 8 in Xalatan group&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=15 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=15 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The comparison between the treatment groups was performed by using a logistic regression model which incorporated the baseline IOP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=16 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=16 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The comparison between the treatment groups was performed by using a logistic regression model which incorporated the baseline IOP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=17 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=17 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The comparison between the treatment groups was performed by using a logistic regression model which incorporated the baseline IOP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=18 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=18 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The comparison between the treatment groups was performed by using a logistic regression model which incorporated the baseline IOP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP Reduction of &gt;=2 mmHg From Baseline to Week 8</title>
        <description>Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP Reduction of &gt;=2 mmHg From Baseline to Week 8</title>
          <description>Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The comparison between the treatment groups was performed by using a logistic regression model which incorporated the baseline IOP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP Reduction of &gt;=3 mmHg From Baseline to Week 8</title>
        <description>Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP Reduction of &gt;=3 mmHg From Baseline to Week 8</title>
          <description>Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The level of statistical significance was the two-sided 0.05. Primary as well as secondary endpoints were tested, but because the tests of the secondary endpoints are exploratory, no adjustment to p-values was made for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The comparison between the treatment groups was performed by using a logistic regression model which incorporated the baseline IOP.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>KP2035 Group</title>
          <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="E2">
          <title>Xalatan Group</title>
          <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
        </group>
      </group_list>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

